Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Chronic kidney disease progression in patients with resistant hypertension subject to 2 therapeutic strategies: Intensification with loop diuretics vs aldosterone antagonists.

Verdalles U, Goicoechea M, García de Vinuesa S, Torres E, Hernández A, Verde E, Pérez de José A, Luño J.

Nefrologia. 2019 Aug 23. pii: S0211-6995(19)30122-5. doi: 10.1016/j.nefro.2019.04.012. [Epub ahead of print] English, Spanish.

2.

Obesity and chronic kidney disease progression-the role of a new adipocytokine: C1q/tumour necrosis factor-related protein-1.

Barbieri D, Goicoechea M, Sánchez-Niño MD, Ortiz A, Verde E, Verdalles U, Pérez de José A, Delgado A, Hurtado E, Sánchez-Cámara L, Lopez-Lazareno N, García-Prieto A, Luño J.

Clin Kidney J. 2018 Oct 11;12(3):420-426. doi: 10.1093/ckj/sfy095. eCollection 2019 Jun.

3.

Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial.

de Morales AM, Goicoechea M, Verde E, Carbayo J, Barbieri D, Delgado A, Verdalles U, de Jose AP, Luño J.

J Nephrol. 2019 Aug;32(4):581-587. doi: 10.1007/s40620-019-00607-0. Epub 2019 Apr 4.

PMID:
30949987
4.

High convective volumes are associated with improvement in metabolic profile in diabetic patients on online haemodiafiltration.

Macías N, Abad S, Vega A, Cedeño S, Santos A, Verdalles Ú, Linares T, Aragoncillo I, Galán I, García-Prieto A, Luño J, López Gómez JM.

Nefrologia. 2019 Mar - Apr;39(2):168-176. doi: 10.1016/j.nefro.2018.08.005. Epub 2018 Nov 19. English, Spanish.

5.

Influence of calcium concentration in haemodialysis fluid on blood pressure control.

Ampuero Mencía J, Vega A, Abad S, Ruiz Caro C, Verdalles Ú, López Gómez JM.

Nefrologia. 2019 Jan - Feb;39(1):44-49. doi: 10.1016/j.nefro.2018.04.008. Epub 2018 Jul 31. English, Spanish.

6.

Impact of the application of the JNC 8 and KDIGO-2013 guidelines on hypertension and lipid control in a Nephrology outpatient clinic.

Galán I, Verdalles Ú, García de Vinuesa M, Quiroga B, Goicoechea M, Pérez A, Verde E, Luño J.

Nefrologia. 2018 Jul - Aug;38(4):379-385. doi: 10.1016/j.nefro.2017.10.003. English, Spanish.

7.

Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study).

Goicoechea M, de Vinuesa SG, Quiroga B, Verde E, Bernis C, Morales E, Fernández-Juárez G, de Sequera P, Verdalles U, Delgado R, Torres A, Arroyo D, Abad S, Ortiz A, Luño J.

Cardiovasc Drugs Ther. 2018 Jun;32(3):255-263. doi: 10.1007/s10557-018-6802-1.

PMID:
29943364
8.

Impact of anticoagulation and platelet antiaggregation on anaemia and haemorragic events in patients with chronic kidney disease stages 3 and 4.

García-Prieto A, Goicoechea M, Linares T, Panizo N, García de Vinuesa MS, Verdalles Ú, Verde E, Pérez de José A, Luño J.

Med Clin (Barc). 2018 Dec 21;151(12):476-480. doi: 10.1016/j.medcli.2018.01.021. Epub 2018 Mar 2. English, Spanish.

PMID:
29503026
9.

Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients.

Goicoechea M, Sanchez-Niño MD, Ortiz A, García de Vinuesa S, Quiroga B, Bernis C, Morales E, Fernández-Juarez G, de Sequera P, Verdalles U, Verde E, Luño J.

Prostaglandins Leukot Essent Fatty Acids. 2017 Oct;125:8-13. doi: 10.1016/j.plefa.2017.08.009. Epub 2017 Aug 24.

PMID:
28987723
10.

Hyperuricemia is associated with progression of chronic kidney disease in patients with reduced functioning kidney mass.

Galán I, Goicoechea M, Quiroga B, Macías N, Santos A, García de Vinuesa MS, Verdalles Ú, Cedeño S, Verde E, Pérez de José A, García A, Luño J.

Nefrologia. 2018 Jan - Feb;38(1):73-78. doi: 10.1016/j.nefro.2017.04.006. Epub 2017 Aug 30. English, Spanish.

11.

Cardiovascular risk prediction in chronic kidney disease patients.

Cedeño Mora S, Goicoechea M, Torres E, Verdalles Ú, Pérez de José A, Verde E, García de Vinuesa S, Luño J.

Nefrologia. 2017 May - Jun;37(3):293-300. doi: 10.1016/j.nefro.2016.10.002. Epub 2017 May 8. English, Spanish.

12.

Prevalence and characteristics of patients with resistant hypertension and chronic kidney disease.

Verdalles Ú, Goicoechea M, Garcia de Vinuesa S, Quiroga B, Galan I, Verde E, Perez de Jose A, Luño J.

Nefrologia. 2016 Sep - Oct;36(5):523-529. doi: 10.1016/j.nefro.2016.04.003. Epub 2016 Jul 18. English, Spanish.

13.

The effect of some medications given to CKD patients on vitamin D levels.

Yuste C, Quiroga B, de Vinuesa SG, Goicoechea MA, Barraca D, Verdalles U, Luño J.

Nefrologia. 2015;35(2):150-6. doi: 10.1016/j.nefro.2015.05.016. Epub 2015 Jun 23.

14.

Dose equivalence between continuous erythropoietin receptor activator (CERA), Darbepoetin and Epoetin in patients with advanced chronic kidney disease.

Vega A, Abad S, Verdalles U, Aragoncillo I, Velazquez K, Quiroga B, Escudero V, López-Gómez JM.

Hippokratia. 2014 Oct-Dec;18(4):315-8.

15.

Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?

Verdalles U, García de Vinuesa S, Goicoechea M, Macías N, Santos A, Perez de Jose A, Verde E, Yuste C, Luño J.

Nephrology (Carlton). 2015 Aug;20(8):567-71. doi: 10.1111/nep.12475.

PMID:
25818266
16.

Interarm systolic blood pressure as a predictor of cardiovascular events in patients with chronic kidney disease.

Quiroga B, Galán I, García de Vinuesa S, Goicoechea M, Verdalles Ú, Luño J.

Nephrol Dial Transplant. 2015 May;30(5):801-6. doi: 10.1093/ndt/gfv059. Epub 2015 Mar 9.

PMID:
25753805
17.

Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial.

Goicoechea M, Garcia de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A, Pérez de Jose A, Cedeño S, Linares T, Luño J.

Am J Kidney Dis. 2015 Apr;65(4):543-9. doi: 10.1053/j.ajkd.2014.11.016. Epub 2015 Jan 13.

PMID:
25595565
18.

Evaluation of methods based on creatinine and cystatin C to estimate glomerular filtration rate in chronic kidney disease.

Vega A, García de Vinuesa S, Goicoechea M, Verdalles U, Martínez-Pueyo ML, Chacón A, Quiroga B, Luño J.

Int Urol Nephrol. 2014 Jun;46(6):1161-7. doi: 10.1007/s11255-013-0607-8. Epub 2013 Nov 22.

PMID:
24265040
19.

Urate reduction and renal preservation: what is the evidence?

Macías N, Goicoechea M, de Vinuesa MS, Verdalles U, Luño J.

Curr Rheumatol Rep. 2013 Dec;15(12):386. doi: 10.1007/s11926-013-0386-3. Review.

PMID:
24203097
20.

Cardiovascular events and mortality in chronic kidney disease (stages I-IV).

Quiroga B, Verdalles Ú, Reque J, García de Vinuesa S, Goicoechea M, Luño J.

Nefrologia. 2013;33(4):539-45. doi: 10.3265/Nefrologia.pre2013.May.11895. English, Spanish.

21.

Utility of bioimpedance spectroscopy (BIS) in the management of refractory hypertension in patients with chronic kidney disease (CKD).

Verdalles U, de Vinuesa SG, Goicoechea M, Quiroga B, Reque J, Panizo N, Arroyo D, Luño J.

Nephrol Dial Transplant. 2012 Dec;27 Suppl 4:iv31-5. doi: 10.1093/ndt/gfs420.

PMID:
23258808
22.

Hypercalcemia as a side effect of potassium binding agents.

Arroyo D, Panizo N, García de Vinuesa S, Goicoechea M, Verdalles U, Luño J.

Nefrologia. 2012;32(5):655-8. doi: 10.3265/Nefrologia.pre2012.Jun.11500. English, Spanish.

23.

Calciphylaxis in end-stage renal disease patients.

Verdalles U, García de Vinuesa S, Luño J.

Nephrol Dial Transplant. 2012 Sep;27(9):3663; author reply 3663-4. doi: 10.1093/ndt/gfs271. Epub 2012 Jul 17. No abstract available.

PMID:
22805222
24.

Intraindividual interleukin-6 variations on the cardiovascular prognosis of patients with chronic renal disease.

Goicoechea M, Quiroga B, García de Vinuesa S, Verdalles U, Reque J, Panizo N, Arroyo D, Santos A, Macías N, Luño J.

Ren Fail. 2012;34(8):1002-9. doi: 10.3109/0886022X.2012.696469. Epub 2012 Jun 29.

PMID:
22746155
25.

Renal infarction in patient with long-standing ventricular aneurysm.

Quiroga B, Santos A, Verdalles U, Reque J, García de Vinuesa S, Goicoechea M, Pérez de José A, Macías N, Luño J.

Nefrologia. 2012;32(2):233-4. doi: 10.3265/Nefrologia.pre2012.Feb.11377. English, Spanish. No abstract available.

26.

Chronic kidney disease progression in patients with autosomal dominant polycystic kidney disease.

Panizo N, Goicoechea M, García de Vinuesa S, Arroyo D, Yuste C, Rincón A, Verdalles U, Ruiz-Caro C, Quiroga B, Luño J.

Nefrologia. 2012;32(2):197-205. doi: 10.3265/Nefrologia.pre2011.Dec.11177. Epub 2012 Jan 27. English, Spanish.

27.

Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial.

Goicoechea M, García de Vinuesa S, Quiroga B, Verdalles U, Barraca D, Yuste C, Panizo N, Verde E, Muñoz MA, Luño J.

J Nephrol. 2012 Nov-Dec;25(6):969-75. doi: 10.5301/jn.5000077.

PMID:
22241639
28.

The phase angle of the electrical impedance is a predictor of long-term survival in dialysis patients.

Abad S, Sotomayor G, Vega A, Pérez de José A, Verdalles U, Jofré R, López-Gómez JM.

Nefrologia. 2011;31(6):670-6. doi: 10.3265/Nefrologia.pre2011.Sep.10999. English, Spanish.

29.

[Cardiac markers in different degrees of chronic kidney disease: influence of inflammation and previous heart disease].

Quiroga B, Goicoechea M, García de Vinuesa S, Verde E, Verdalles U, Yuste C, Reque J, Luño J.

Med Clin (Barc). 2012 Jun 30;139(3):98-102. doi: 10.1016/j.medcli.2011.05.014. Epub 2011 Jul 31. Spanish.

PMID:
21807382
30.

Acute kidney failure in the context of a Tako-Tsubo syndrome.

Arroyo D, Panizo N, Verdalles U, Vázquez-Álvarez ME, Barraca D, Quiroga B, Luño J.

Nefrologia. 2011;31(4):493-4. doi: 10.3265/Nefrologia.pre2011.Apr.10879. English, Spanish. No abstract available.

31.

Factors related to the absence of anemia in hemodialysis patients.

Verdalles U, Abad S, Vega A, Ruiz Caro C, Ampuero J, Jofre R, Lopez-Gomez JM.

Blood Purif. 2011;32(1):69-74. doi: 10.1159/000323095. Epub 2011 Feb 24.

PMID:
21346339
32.

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.

Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, Arroyo D, Luño J.

Clin J Am Soc Nephrol. 2010 Aug;5(8):1388-93. doi: 10.2215/CJN.01580210. Epub 2010 Jun 10.

33.

Factors predicting mortality in elderly patients on dialysis.

Verdalles U, Abad S, Aragoncillo I, Villaverde M, Jofre R, Verde E, Vega A, López-Gómez JM.

Nephron Clin Pract. 2010;115(1):c28-34. doi: 10.1159/000286347. Epub 2010 Feb 19.

PMID:
20173347
34.

[Atheroembolism in transplanted kidney].

Aragoncillo I, Rodríguez M, Niembro E, Rengel M, Verdalles U, Anaya F.

Nefrologia. 2009;29(3):274-5. doi: 10.3265/Nefrologia.2009.29.3.4896.en.full. Spanish. No abstract available.

35.

Serum fibrinogen levels are an independent predictor of mortality in patients with chronic kidney disease (CKD) stages 3 and 4.

Goicoechea M, de Vinuesa SG, Gómez-Campderá F, Aragoncillo I, Verdalles U, Mosse A, Luño J.

Kidney Int Suppl. 2008 Dec;(111):S67-70. doi: 10.1038/ki.2008.519.

36.

Calciphylaxis: a severe complication of the cardiometabolic syndrome in patients receiving hemodialysis.

Verdalles U, Cueva Pde L, Verde E, Vinuesa SG, Goicoechea M, Mosse A, Lopez-Gomez JM, Luño J.

J Cardiometab Syndr. 2008 Winter;3(1):63-7. No abstract available.

37.

[Therapeutic guidelines fulfillment in clinical practice in patients with chronic kidney disease (CKD)].

Verdalles U, García de Vinuesa S, Goicoechea M, Gómez Campderá F, Luño J.

Nefrologia. 2007;27(3):320-8. Spanish.

38.

Erdheim-Chester disease: a rare cause of renal failure.

Verdalles U, Goicoechea M, García de Vinuesa S, Mosse A, Luño J.

Nephrol Dial Transplant. 2007 Jun;22(6):1776-7. Epub 2007 Mar 29. No abstract available.

PMID:
17395655

Supplemental Content

Loading ...
Support Center